Pidotimod vs Thymopentin
Head-to-head comparison of Pidotimod (3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid) and Thymopentin (L-Arginyl-L-Lysyl-L-Aspartyl-L-Valyl-L-Tyrosine) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Pidotimod | Thymopentin |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | 3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid | L-Arginyl-L-Lysyl-L-Aspartyl-L-Valyl-L-Tyrosine |
| Molecular Weight | 244.27 Da | 676.78 Da |
| Half-Life | 3-4 h | 10-30 min |
| Amino Acids | 2 | 5 |
| Typical Dose | 400-800 mg/day | 1 mg |
| Route | Oral | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 200 | 90 |
| Research Status | Clinical | Clinical |
Pidotimod Benefits
- ✓oral-immune-support
- ✓respiratory-infection-adjunct
- ✓innate-immunity
- ✓adaptive-immunity-support
Thymopentin Benefits
- ✓t-cell maturation
- ✓helper-suppressor balance
- ✓immune recovery
- ✓antiviral-adjunct research
Pidotimod Dosing
400 mg PO BID|typically 15-30 days|repeated seasonal cycles in studies
Thymopentin Dosing
1 mg SC or IM|2-3x weekly|4-8 week study cycles
Pidotimod Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠rash
Thymopentin Side Effects
- ⚠injection-site redness
- ⚠mild fever
- ⚠headache
Research Overview
Pidotimod
Pidotimod has human data in recurrent infections, especially where immune stimulation or reduced infection frequency is the target. Published work commonly reports improvements in phagocyte function, mucosal defense, and fewer respiratory infection episodes.
Thymopentin
Thymopentin has a long history of preclinical and clinical investigation as a thymic peptide immunomodulator. Published studies report effects on T-cell subsets, cytokine responses, and immune recovery in recurrent infection settings.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.